Clinical trials: HSV-2 Infection
Uterine Cervical Neoplasms
First-in-human (FIH) Phase I Trial of BS-006 in Cervical Cancer
This is a two-stage phase I clinical trial with oncolytic viruses BS-006 in recurrent or metastasis cervical cancer patients who failed in second line treatment.
- Trial name
- CC-OV01 (NCT05393440)
- Testing
- BS-006
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Zhongnan Hospital
Genital Herpes
Trial Evaluating Safety, Tolerability and Immune Response of AG-707
This is a randomized, multi-center, sequential, dose-escalating study of three dose cohorts of AG-707. Individuals who meet all of the inclusion and exclusion criteria for eligibility will be randomized to receive either AG-707…
- Trial name
- NCT00231049
- Testing
- AG-707
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Agenus Inc.
Chronic Hepatitis C Infection
Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I)
The purpose of this study is to study the effects of valacyclovir on patients who have hepatitis C and antibodies to herpes simplex type-2. Herpes simplex type 2 is a virus which causes genital herpes.
- Trial name
- NCT01453075
- Testing
- Valacyclovir
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
HIV Infections, Sexually Transmitted Diseases
Trial of Male Circumcision: HIV, Sexually Transmitted Disease (STD) and Behavioral Effects in Men, Women and the Community
This randomized controlled trial conducted in Rakai District, Uganda, has enrolled 997 HIV positive men and 500 men who declined to learn HIV results (regardless of HIV status).
- Conditions
- HIV Infections, Sexually Transmitted Diseases, Papillomavirus Infections, Genital Herpes
- Trial name
- NCT00124878
- Testing
- Male circumcision
- Where
- Uganda
- Volunteers
- 5,200 people, healthy volunteers welcome
- Sponsor
- Wawer, Maria J., M.D.
Herpes Labialis
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
Eligible subjects will be randomized to receive VALTREX 1g or placebo once daily for 60 days in a two-way crossover study with a washout period of 7 days in between.
- Trial name
- NCT00306293
- Testing
- valacyclovir
- Where
- 18 sites in United States
- Volunteers
- 70 people
- Sponsor
- GlaxoSmithKline
HSV-2 Infection, Genital Herpes
The VIBLOK SAfety and perFormancE Trial
Genital herpes has a high prevalence in industrialized as well as developing countries. Genital herpes causes genital ulcers, increases risk for acquiring HIV infection, and may be transmitted mother to child during birth with…
- Trial name
- SAFE (NCT03080961)
- Testing
- VIBLOK barrier cream
- Where
- 3 sites in Netherlands
- Volunteers
- 82 people
- Sponsor
- CLJI Worldwide
Herpes Simplex 2, Meningitis, Viral
Aciclovir Versus Placebo for HSV-2 Meningitis
To determine whether active treatment with (val)acyclovir is superior for treatment of viral meningitis compared with placebo assessed by numbers meeting a primary, objective endpoint at 7 days after randomisation
- Trial name
- AMEN (NCT05452928)
- Testing
- Acyclovir 50 MG/ML
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Jacob Bodilsen
Herpes Simplex
A Study on the Reactogenicity, Safety and Immune Response of a Targeted Immunotherapy Against HSV in Healthy Japanese Participants Aged 18-40 Years
The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of 2 formulations of Herpes Simplex Virus (HSV)-Targeted Immunotherapy (HSVTI) in HSV-2 seronegative ethnic Japanese adults aged 18-40 years.
- Trial name
- TH HSV REC-004 (NCT05989672)
- Testing
- HSVTI Formulation 1, HSVTI Formulation 2
- Where
- Japan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Genitalis, HIV Infection
Randomised Controlled Trial Assessing the Impact of Genital Herpes Suppressive Therapy on HIV Shedding
Genital herpes is a long-life sexually transmitted diseases which infects a large proportion of women in Africa. Its clinical symptoms are painful sores on the genitals, which heals after a few days.
- Trial name
- NCT00158509
- Testing
- Valacyclovir
- Where
- Burkina Faso
- Volunteers
- 215 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Solid Tumor, Melanoma
OH2 Injection in Solid Tumors
This phase I study evaluates the safety and efficacy of OH2 as single agent or in combination with Keytruda, an anti-PD-1 antibody, in patients with malignant solid tumors (Melanoma).
- Trial name
- NCT04386967
- Testing
- OH2 injection, Keytruda
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Binhui Biopharmaceutical Co., Ltd.
Recurrent Genital Herpes
Evaluating Safety and Efficacy of Repeat Doses of UB-621in Adult Patients With Recurrent Genital Herpes
To evaluate the efficacy of repeat-dose UB-621 for the recurrent genital HSV-2 infection To evaluate the safety and tolerance of repeat-dose UB-621 for the recurrent HSV-2 infection To evaluate the pharmacokinetics of repeat-dose…
- Trial name
- NCT04979975
- Testing
- UB-621 low-dose, UB-621 high-dose
- Volunteers
- 200 people
- Sponsor
- UBP Greater China (Shanghai) Co., Ltd
HIV, Hepatitis C
A Methadone Maintenance Treatment Outcome Study in Three Provinces in China
The primary goal of this PHE is to determine the effectiveness of a tailored education program for MMT service providers. It was to be evaluated through methadone dose levels prescribed to new patients after training completion.
- Conditions
- HIV, Hepatitis C, Syphilis, Herpes Simplex Type II
- Trial name
- NCT01315054
- Testing
- MMT provider dosage training, targeted counseling, national guidelines
- Where
- China
- Volunteers
- 4,258 people
- Sponsor
- Centers for Disease Control and Prevention
HIV Infections, Herpes Genitalis
Effect of Male Circumcision on HIV Incidence (ANRS 1265)
Observational studies suggest that male circumcision may provide protection against HIV-1 infection. A randomized, controlled, intervention trial was conducted in a general population of South Africa to test this hypothesis.
- Conditions
- HIV Infections, Herpes Genitalis, Venereal Diseases
- Trial name
- NCT00122525
- Testing
- Male Circumcision
- Where
- South Africa
- Volunteers
- 3,274 people, healthy volunteers welcome
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
HIV, Hepatitis C
Injecting Drug Use Community Intervention Trial
The purpose of this study is to reduce the HIV/HCV incidence among the clients attending community-based methadone maintenance treatment (MMT) , and to prevent the secondary sexual transmission from HIV+ clients to their spouse…
- Conditions
- HIV, Hepatitis C, Syphilis, HSV-2
- Trial name
- NCT01108614
- Testing
- Intervention
- Where
- 5 sites in China
- Volunteers
- 12,000 people
- Sponsor
- National Center for AIDS/STD Control and Prevention, China CDC
HIV Infections, Ulcer
Episodic Acyclovir Therapy for Genital Ulcers
The purpose of this study is to determine if acyclovir episodic treatment has an effect in ulcer healing and if it should be added to the syndromic management of genital ulcer disease.
- Conditions
- HIV Infections, Ulcer, Herpes Simplex
- Trial name
- NCT00164424
- Testing
- Acyclovir
- Where
- 2 sites in South Africa
- Volunteers
- 613 people
- Sponsor
- Centers for Disease Control and Prevention
Genital Herpes
A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of an mRNA Vaccine Against Herpes Simplex Virus Type 2 (HSV-2) Post-Vaccination
A Preliminary Evaluation of the Safety and Immunogenicity Post-Vaccination with Different Doses of an mRNA Vaccine against Herpes Simplex Virus Type 2 (HSV-2) in Populations with Different Serostatus
- Trial name
- NCT07330440
- Testing
- Low-Dose Cohort, Mid-Dose Cohort, High-Dose Cohort
- Where
- China
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.
HIV Infections, HSV-2 Infection
Immunogenetic Modulators of Mucosal Protection From HIV-1
This is a single site, prospective, observational study that seeks to assess changes in mucosal immunity that occur as a result of HIV-1 exposure, HSV-2 infection, and/or pre-exposure prophylaxis (PrEP) usage to prevent HIV-1…
- Trial name
- Kinga (NCT03701802)
- Where
- Kenya
- Volunteers
- 812 people, healthy volunteers welcome
- Sponsor
- University of Washington
Genital Herpes Simplex Type 2
Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 Study
This is a voluntary study to allow subjects who received placebo while on GEN-003-002 to be randomized, in a blinded manner, to 1 of 6 active combinations of GEN-003 and Matrix-M2.
- Trial name
- NCT02300142
- Testing
- GEN-003 Vaccine (30μg of each antigen), GEN-003 Vaccine (60μg of each antigen), Matrix-M2 Adjuvant (25μg)
- Where
- 16 sites in United States
- Volunteers
- 37 people
- Sponsor
- Genocea Biosciences, Inc.
HIV Infections, Herpes Genitalis
HIV and Genital Herpes Among High-Risk Men Who Have Sex With Men (MSM) in Lima, Peru
The purpose of this study is to provide biomedical and behavioral information that is necessary for planning and starting HIV prevention trials in Lima, Peru.
- Conditions
- HIV Infections, Herpes Genitalis, HIV Seronegativity, Syphilis
- Trial name
- NCT00023582
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection, Herpes Simplex
HSV-2 Suppression to Reduce HIV-1 Levels in HIV-1, HSV-2 Co-infected Men.
Over 80% of HIV-1 infected persons are also seropositive for HSV-2. Increasingly, clinical and epidemiologic evidence show the role of HSV in increasing HIV infectiousness.
- Conditions
- HIV Infection, Herpes Simplex, Sexually Transmitted Diseases
- Trial name
- NCT00378976
- Testing
- valacyclovir
- Where
- Peru
- Volunteers
- 20 people
- Sponsor
- University of Washington